The chronic kidney disease clinical trial landscape in 2026
Chronic kidney disease affects roughly 850 million people worldwide, yet the treatment landscape remained largely static for decades after ACE inhibitors and ARBs became standard of care. That stasis is now breaking open. The 2020s have produced the most productive CKD pipeline in the disease's history, driven by SGLT2 inhibitors proving renoprotective benefit independent of glycemia, a new generation of non-steroidal mineralocorticoid receptor antagonists (MRAs), and a wave of HIF-prolyl hydroxylase inhibitor (HIF-PHI) programs targeting anemia of CKD.
The 114 active trials in our database span a wide mechanistic range. IgA nephropathy — long an orphan within nephrology — has emerged as one of the most competitive indication sub-segments in 2025–2026, with approved therapies from Omeros (sparsentan via Travere) and Calliditas (budesonide, Tarpeyo), plus pipeline entrants targeting BAFF/APRIL signaling, complement, and endothelin. Diabetic kidney disease (DKD) remains the largest addressable sub-indication, drawing sustained investment from large pharma and specialty biotech alike.
Beyond mechanism innovation, trial design is evolving. Regulators are now accepting eGFR slope as a primary endpoint in shorter trials, compressing development timelines and creating a faster read-through opportunity for BD teams tracking mid-stage data.
- SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) — DKD and non-diabetic CKD
- Non-steroidal MRAs — finerenone (Bayer/approved), next-gen follow-ons in Phase 2
- HIF-PHI agents — daprodustat, vadadustat, roxadustat for CKD anemia
- Complement inhibitors — IgAN sub-indication (iptacopan, cemdisiran)
- BAFF/APRIL pathway — IgAN (atacicept, telitacicept)
- Endothelin receptor antagonists — sparsentan (dual AT1/ETA) for FSGS and IgAN
Track every new CKD trial automatically
ClinicalTrials.gov updates daily. Our pipeline monitors it for you and delivers a clean digest every morning.
Get Free Alerts — No Credit CardWhat we monitor for chronic kidney disease
Our system pulls from the ClinicalTrials.gov API every day. For a CKD watch profile, you can configure alerts for:
- Keywords: "chronic kidney disease," "CKD," "diabetic kidney disease," "IgA nephropathy," "FSGS," "nephrotic syndrome," "ESRD," "eGFR," "proteinuria," "renal fibrosis"
- Phase filters: Phase 1, Phase 2, Phase 3, or Phase 2/3 only
- Sponsor type: industry-sponsored, NIH/federal, academic medical center
- Study status: recruiting, not yet recruiting, active not recruiting
- Enrollment size: filter for large Phase 3 outcome trials (500+ subjects) vs. early mechanistic studies
IgA nephropathy — the most competitive CKD sub-indication in 2026
IgA nephropathy (IgAN) has undergone a transformation from an underserved niche to one of the most watched indications in nephrology. Sparsentan (Filspari) received accelerated approval from the FDA in 2023, followed by full approval in 2024 based on the PROTECT trial's protein-to-creatinine ratio data. Calliditas' budesonide formulation (Tarpeyo/Kinpeygo) is approved in the US and EU. That regulatory momentum has attracted a second wave of entrants.
Ongoing Phase 2 and 3 programs in IgAN include iptacopan (Novartis, factor B complement inhibitor), cemdisiran/inclisiran combination (Alnylam), atacicept (Vera Therapeutics, BAFF/APRIL dual inhibitor), and sibeprenlimab (Visterra/Otsuka, APRIL-targeting antibody). The overlap of approved products and late-stage pipeline means competitive intelligence on new trial initiations is directly actionable for licensing desks and portfolio strategy teams.
BD professionals tracking IgAN need to see new trials on day one — a Phase 2 initiation by a well-capitalized biotech is often the first public signal of a partnering or M&A process. DataLookout surfaces those registrations the morning they appear on ClinicalTrials.gov.
Active Phase 3 CKD Pipeline — 2026
Key industry-sponsored Phase 3 trials currently active or recruiting in chronic kidney disease:
| Drug / Program | Mechanism | Sponsor | Indication | Status |
|---|---|---|---|---|
| VX-147 / Inaxaplin | APOL1 channel blocker | Vertex Pharmaceuticals | APOL1-mediated proteinuric CKD | Recruiting |
| Zibotentan + dapagliflozin (ZENITH) | ETA antagonist + SGLT2i | AstraZeneca | CKD with high proteinuria | Active (not recruiting) |
| BI 690517 + empagliflozin (EASi-KIDNEY) | MRA + SGLT2i combination | Boehringer Ingelheim | CKD with heart failure | Recruiting |
| Orforglipron (ATTAIN-Outcomes) | Oral GLP-1 receptor agonist | Eli Lilly | CKD with ASCVD / cardiorenal | Recruiting |
| Retatrutide (TRIUMPH-Outcomes) | GLP-1/GIP/glucagon triagonist | Eli Lilly | CKD with obesity / CV risk | Active (not recruiting) |
| Mezagitamab (IgAN) | Anti-CD38 mAb | Takeda | Primary IgA nephropathy | Recruiting |
| REACT cell therapy (Prokidney) | Renal autologous cell therapy | ProKidney | Diabetic kidney disease | Recruiting |
The cardiorenal GLP-1 wave: oral agents expand beyond diabetes
The cardiorenal protective effects of GLP-1 receptor agonists were established with semaglutide in the FLOW trial (2024), which demonstrated a 24% reduction in kidney disease progression in CKD patients with type 2 diabetes. This has triggered a second wave of CKD outcome trials for next-generation GLP-1 agents:
- Orforglipron (Eli Lilly) — oral, non-peptide GLP-1 agonist (no injection); ATTAIN-Outcomes is a Phase 3 cardiorenal outcomes trial specifically in patients with ASCVD and/or CKD; if successful, establishes an oral GLP-1 option for the nephrology patient who won't self-inject
- Retatrutide (Eli Lilly) — triple GIP/GLP-1/glucagon agonist with superior weight loss vs. semaglutide in early trials; TRIUMPH-Outcomes includes CKD endpoints; cardiorenal implications of glucagon co-agonism are a key monitoring question
- CKD without diabetes — the frontier question: do GLP-1 agents provide renoprotection in non-diabetic CKD? Multiple investigator-initiated trials are now examining this hypothesis; any Phase 3 initiation in non-diabetic CKD by a major sponsor would be a high-significance registration event
APOL1-mediated kidney disease: precision medicine enters nephrology
VX-147 (inaxaplin) is the first targeted therapy for APOL1-mediated kidney disease — a genetically defined CKD subtype driven by gain-of-function variants (G1 and G2) in the APOL1 gene. These variants are present in ~13% of African Americans and dramatically elevate CKD risk, accounting for a disproportionate share of kidney failure in Black patients. Inaxaplin works by blocking the APOL1 ion channel in podocytes, preventing the cellular damage that drives proteinuria and progressive GFR loss. Phase 2 data showed 48% reduction in proteinuria with inaxaplin vs. placebo. The ongoing Phase 2/3 adaptive trial (currently recruiting) is the pivotal program. BD teams tracking precision nephrology should have this trial registered as a priority watch — any interim analysis or enrollment completion is a licensing signal.
Who uses CKD trial monitoring
- Pharma and biotech BD teams — tracking competitor program initiations, Phase 2 transitions, and enrollment completions across DKD, IgAN, FSGS, and CKD anemia sub-indications
- Renal disease investors — monitoring the pipeline for catalysts: Phase 3 enrollments, interim data triggers, and NDA-relevant completions
- Nephrology CROs — identifying new sponsor relationships and recruitment opportunities across eGFR-endpoint and anemia trials
- Medical affairs teams at approved product sponsors — watching new entrants in IgAN, FSGS, and DKD who may compete with marketed assets
- Academic nephrology research groups — staying current on industry-sponsored trials that may seek investigator sites
Stop monitoring ClinicalTrials.gov manually
Set up your CKD alert profile in 2 minutes. Daily digest delivered to your inbox. Cancel anytime.
Start Free — No Credit CardHow DataLookout works
We run a direct API connection to ClinicalTrials.gov every morning, collecting all new and updated trials. Our matching engine compares each trial against your profile — condition keywords, drug targets, phase, sponsor type, and study status. Only relevant trials reach your inbox.
Your daily digest includes: trial title, phase, sponsor, current status, enrollment target, primary endpoint, and a direct link to the ClinicalTrials.gov record. No noise, no duplicate alerts.
Pricing
Free — $0 forever: 1 disease tracker, weekly digest, ClinicalTrials.gov monitoring. No credit card required.
Starter — $29/month: 5 disease/keyword profiles, daily digest, all phase and sponsor filters. Best for individual analysts.
Pro — $99/month: Unlimited profiles, daily digest, priority support. Best for BD and CI teams.
Related Pages
- IgA nephropathy clinical trials — dedicated tracker for the most competitive CKD sub-indication in 2026
- Diabetes clinical trials — GLP-1, SGLT2, and DKD pipeline from the T2D angle
- Cardiovascular clinical trials — cardiorenal programs tracked from the heart failure and outcomes side
- Amyloidosis clinical trials — TTR amyloidosis programs affecting both heart and kidney